This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ImmunoGen (IMGN) Files BLA for Lead Drug in Ovarian Cancer
by Zacks Equity Research
ImmunoGen (IMGN) seeks accelerated approval from the FDA for its lead candidate, mirvetuximab soravtansine, in previously treated platinum-resistant ovarian cancer. This pushes the stock price up.
Roche (RHHBY) Late-Stage Study for ES-SCLC Fails to Meet Goal
by Zacks Equity Research
Roche (RHHBY) phase III SKYSCRAPER-02 study assessing tiragolumab plus Tecentriq and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer did not meet co-primary endpoint of progression-free survival.
JAZZ Initiates Zepzelca Basket Study in Advanced Solid Tumors
by Zacks Equity Research
JAZZ enrolls the first patient in a mid-stage study to evaluate its lung cancer drug, Zepzelca, in advanced and difficult-to-treat cancer indications in previously-treated patients.
Halozyme (HALO) Inks Collaboration Deal With Chugai Pharma
by Zacks Equity Research
Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.
Amgen (AMGN) Outperforms Industry This Year So Far: What Next?
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why
by Zacks Equity Research
Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang.
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
Exelixis (EXEL) Announces Final Results From HCC Study
by Zacks Equity Research
Exelixis (EXEL) does not intend to submit a supplemental new drug application to the FDA for Cabometyx in patients with previously untreated advanced hepatocellular carcinoma.
AbbVie (ABBV) Inks Deal for Neuropsychiatric Conditions
by Zacks Equity Research
AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar.
Sanofi's (SNY) Hemophilia A Candidate Meets Study Endpoints
by Zacks Equity Research
Sanofi (SNY) and Sobi's factor VIII replacement therapy candidate, efanesoctocog alfa, achieves clinically meaningful prevention of bleeds in people with severe hemophilia A
Adaptive Biotechnologies (ADPT) Rises on Restructuring Plans
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) announces reorganization of its business around MRD and Immune Medicine to drive future growth. The company hires a market veteran in health care as its new CFO.
AbbVie (ABBV) Outperforms Industry This Year So Far: What Next?
by Zacks Equity Research
AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag
by Zacks Equity Research
Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. Nevertheless, the pipeline progress is encouraging.
Sarepta (SRPT) Q4 Earnings Beat, DMD Drugs Sales Robust
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the fourth quarter. The company also raises revenue guidance for the year. Stock down in after-market trading.
ImmunoGen (IMGN) Q4 Earnings and Sales Outpace Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports a narrower-than-expected loss for fourth-quarter 2021. It also beats revenue estimates. Post the announcement, the share price rises.
Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues
by Zacks Equity Research
Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.
Prothena (PRTA) Q4 Earnings Beat, Pipeline Progress in Focus
by Zacks Equity Research
Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.
Top Analyst Reports for Adobe, Altria Group & Marriott International
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), Altria Group, Inc. (MO), and Marriott International, Inc. (MAR).
Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.
Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate
by Zacks Equity Research
Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.
Amgen's (AMGN) Q4 Earnings Top Estimates, Product Sales Fall
by Zacks Equity Research
Amgen (AMGN) beats Q4 estimates for earnings but misses the same for sales. Higher Other Revenue for manufacturing Eli Lilly's COVID-19 antibody boost sales growth.
Regeneron (REGN) Beats on Q4 Earnings, Gains on REGEN-COV
by Zacks Equity Research
Regeneron (REGN) Q4 earnings beat estimates and sales record strong year-over-year growth on the solid performance of REGEN-COV as well as Eylea and Dupixent.
Biogen (BIIB) Q4 Earnings Top, Stock Down on Weak 2022 View
by Zacks Equity Research
Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The stock declines on weak sales and earnings guidance for 2022.
Roche's (RHHBY) 2021 Earnings, Sales Grow on COVID-19 Tests
by Zacks Equity Research
Roche (RHHBY) performance in the fourth quarter and 2021 was encouraging, driven by demand for COVID-19 tests and recovery in pharma sales. However, sales are expected to slow down in 2022.
Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing
by Zacks Equity Research
Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.